Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calderasib (MK-1084) in KRAS G12C Mutant Advanced Solid Tumors
NCT05067283Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Primary completion
- Feb 2030
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 1, open-label trial of calderasib in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (6 arms), sponsored by Merck & Co. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events at 56 months and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
calderasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05067283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067283.